In summary, in addition to its known tumor-suppressing activity, in specific contexts, and in particular in the absence of p53, p19Arf was found to favor carcinogenesis, exactly as it appears to do in our rhabdomyosarcoma model. Here, TP53 is linked to neoplasm.